Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Xilio Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +1 vs. Q1 2024
- Shares held
- 14.5M
- +2.04M (+16.3%) vs. Q1 2024
- Total value
- $13.7M
- +$270.2K (+2.0%) vs. Q1 2024
- New holders
- 7
- 9 more added
- Sold out
- 6
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 366 | $0 | 0.00% | −167−31.3% | Reduced |
| Qube Research & Technologies Ltd | 4 | $4 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 59 | $56 | 0.00% | −2,685−97.8% | Reduced |
| UBS Group AG | 201 | $191 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 692 | $656 | 0.00% | +692 | New |
| Key Financial Inc | 830 | $786 | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 1,500 | $1.42K | 0.00% | +1,500 | New |
| Tower Research Capital LLC (TRC) | 4,207 | $3.99K | 0.00% | −6,946−62.3% | Reduced |
| Pinnacle Financial Group, LLC | 10,000 | $9.47K | 0.00% | +10,000 | New |
| Dunhill Financial, LLC | 10,274 | $9.73K | 0.01% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 11,925 | $11.3K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 12,205 | $11.6K | 0.00% | −57,993−82.6% | Reduced |
| Two Sigma Securities, LLC | 13,271 | $12.6K | 0.00% | +13,271 | New |
| Avantax Planning Partners, Inc. | 25,000 | $23.7K | 0.00% | +25,000 | New |
| XTX Topco Ltd | 33,289 | $31.5K | 0.00% | +33,289 | New |
| Raymond James & Associates | 38,825 | $36.8K | 0.00% | +38,825 | New |
| Northern Trust Corp | 39,208 | $37.1K | 0.00% | +21,410+120.3% | Added |
| SevenBridge Financial Group, LLC | 41,000 | $37.2K | 0.01% | +10,000+32.3% | Added |
| State Street Corp | 43,390 | $41.1K | 0.00% | +27,700+176.5% | Added |
| BlackRock Inc. | 66,418 | $62.9K | 0.00% | +21,063+46.4% | Added |
| Bridgeway Capital Management, LLC | 71,081 | $67.3K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 182,855 | $173.3K | 0.00% | +98,029+115.6% | Added |
| FIL Ltd | 218,705 | $207.2K | 0.00% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 272,486 | $258.2K | 0.00% | −66,056−19.5% | Reduced |
| Renaissance Technologies LLC | 295,000 | $279.5K | 0.00% | +45,554+18.3% | Added |
| Vanguard Group Inc | 902,531 | $855.1K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,112,740 | $1.05M | 0.00% | +890,835+401.4% | Added |
| FMR LLC | 1,395,853 | $1.32M | 0.00% | −511,818−26.8% | Reduced |
| RiverVest Venture Management LLC | 1,441,444 | $1.37M | 20.01% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.40M | 0.60% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 3,003,259 | $2.85M | 0.09% | +1,562,500+108.4% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,785,450 | $3.59M | 0.39% | +980,037+34.9% | Added |
| Atlas Venture Life Science Advisors, LLC | 0 | $0 | 0.00% | −992,912−100.0% | Sold out |
| PFG Investments, LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −29,500−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −27,500−100.0% | Sold out |
| Summit Trail Advisors, LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −108−100.0% | Sold out |